CR20190148A - Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes - Google Patents
Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantesInfo
- Publication number
- CR20190148A CR20190148A CR20190148A CR20190148A CR20190148A CR 20190148 A CR20190148 A CR 20190148A CR 20190148 A CR20190148 A CR 20190148A CR 20190148 A CR20190148 A CR 20190148A CR 20190148 A CR20190148 A CR 20190148A
- Authority
- CR
- Costa Rica
- Prior art keywords
- lipoic acid
- choline ester
- stabilize
- methods
- acid choline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398748P | 2016-09-23 | 2016-09-23 | |
| PCT/IB2017/055775 WO2018055572A1 (en) | 2016-09-23 | 2017-09-22 | Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190148A true CR20190148A (es) | 2019-09-09 |
Family
ID=60190904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190148A CR20190148A (es) | 2016-09-23 | 2017-09-22 | Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230135366A1 (es) |
| EP (1) | EP3515410A1 (es) |
| JP (1) | JP7091318B2 (es) |
| KR (1) | KR20190065304A (es) |
| CN (1) | CN109906076A (es) |
| AU (1) | AU2017331591B2 (es) |
| BR (1) | BR112019005426A2 (es) |
| CA (1) | CA3037459A1 (es) |
| CL (1) | CL2019000766A1 (es) |
| CO (1) | CO2019002663A2 (es) |
| CR (1) | CR20190148A (es) |
| EC (1) | ECSP19020167A (es) |
| IL (1) | IL265480B (es) |
| JO (1) | JOP20190057A1 (es) |
| MX (1) | MX2019003365A (es) |
| MY (1) | MY194044A (es) |
| PE (1) | PE20191130A1 (es) |
| RU (1) | RU2761519C2 (es) |
| WO (1) | WO2018055572A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113387923A (zh) * | 2020-03-13 | 2021-09-14 | 诺华股份有限公司 | 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法 |
| US20230331692A1 (en) * | 2020-08-27 | 2023-10-19 | Kyowa Pharma Chemical Co., Ltd. | Trisulfide compound and clathrate thereof |
| WO2023079427A1 (en) * | 2021-11-03 | 2023-05-11 | Avaca Pharma Private Limited | Ophthalmic compositions and methods thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| DE102004060914A1 (de) * | 2004-12-17 | 2006-07-06 | Bioghurt Biogarde Gmbh & Co. Kg | Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen |
| EP4082542A1 (en) * | 2009-06-15 | 2022-11-02 | Encore Health, LLC | Dithiol compounds, derivatives, and uses therefor |
| PT2821405E (pt) * | 2009-06-15 | 2016-06-14 | Encore Health Llc | Ésteres de colina para tratar a presbiopia e a catarata |
| CA2941518A1 (en) * | 2014-03-03 | 2015-09-11 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods of use |
| WO2017053646A1 (en) * | 2015-09-24 | 2017-03-30 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations |
-
2017
- 2017-06-16 JO JOP/2019/0057A patent/JOP20190057A1/ar unknown
- 2017-09-22 PE PE2019000709A patent/PE20191130A1/es unknown
- 2017-09-22 KR KR1020197011121A patent/KR20190065304A/ko active IP Right Grant
- 2017-09-22 EP EP17791455.3A patent/EP3515410A1/en active Pending
- 2017-09-22 JP JP2019515804A patent/JP7091318B2/ja active Active
- 2017-09-22 MY MYPI2019001247A patent/MY194044A/en unknown
- 2017-09-22 CR CR20190148A patent/CR20190148A/es unknown
- 2017-09-22 MX MX2019003365A patent/MX2019003365A/es unknown
- 2017-09-22 BR BR112019005426A patent/BR112019005426A2/pt active Search and Examination
- 2017-09-22 AU AU2017331591A patent/AU2017331591B2/en not_active Ceased
- 2017-09-22 RU RU2019111885A patent/RU2761519C2/ru active
- 2017-09-22 CN CN201780058684.2A patent/CN109906076A/zh active Pending
- 2017-09-22 CA CA3037459A patent/CA3037459A1/en active Pending
- 2017-09-22 US US16/335,732 patent/US20230135366A1/en not_active Abandoned
- 2017-09-22 IL IL265480A patent/IL265480B/en unknown
- 2017-09-22 WO PCT/IB2017/055775 patent/WO2018055572A1/en unknown
-
2019
- 2019-03-22 EC ECSENADI201920167A patent/ECSP19020167A/es unknown
- 2019-03-22 CL CL2019000766A patent/CL2019000766A1/es unknown
- 2019-03-22 CO CONC2019/0002663A patent/CO2019002663A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP19020167A (es) | 2019-07-31 |
| MX2019003365A (es) | 2019-11-11 |
| AU2017331591A1 (en) | 2019-04-04 |
| RU2019111885A3 (es) | 2020-12-21 |
| RU2761519C2 (ru) | 2021-12-09 |
| WO2018055572A1 (en) | 2018-03-29 |
| AU2017331591B2 (en) | 2020-04-09 |
| BR112019005426A2 (pt) | 2019-06-25 |
| CN109906076A (zh) | 2019-06-18 |
| JP2019534864A (ja) | 2019-12-05 |
| CA3037459A1 (en) | 2018-03-29 |
| CL2019000766A1 (es) | 2019-08-02 |
| JP7091318B2 (ja) | 2022-06-27 |
| KR20190065304A (ko) | 2019-06-11 |
| JOP20190057A1 (ar) | 2019-03-24 |
| PE20191130A1 (es) | 2019-09-02 |
| MY194044A (en) | 2022-11-09 |
| RU2019111885A (ru) | 2020-10-23 |
| US20230135366A1 (en) | 2023-05-04 |
| EP3515410A1 (en) | 2019-07-31 |
| IL265480B (en) | 2022-09-01 |
| CO2019002663A2 (es) | 2019-06-11 |
| IL265480A (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | |
| CO2019002663A2 (es) | Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes | |
| PH12015502556A1 (en) | Modified release formulation | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| BR112017011623A2 (pt) | composições farmacêuticas e processo para a preparação de uma composição | |
| AR112472A1 (es) | Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas | |
| EP3713553A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| IL258258B (en) | Lipoic acid choline ester preparations and methods for producing biocompatible ophthalmic formulations | |
| EP3600324A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS | |
| ZA202003944B (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| EP3538083A4 (en) | FORMULATIONS FOR THE TREATMENT OF EYE SURFACE DISEASES AND ASSOCIATED METHODS | |
| GB2558494B (en) | Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye | |
| EP3402511A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | |
| IL281217A (en) | Pharmaceutical preparation for controlled release of weak acid drugs and its uses | |
| EP3787609A4 (en) | EYE DROP FORMULATION AND PROLONGED METHOD OF DRUG ADMINISTRATION TO THE RETINAL | |
| EP3340985A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF HYPOXIC-INFLAMMATORY DISEASES | |
| EP3682886A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AORTIC ANEURISM | |
| AU2016905281A0 (en) | Pharmaceutical composition for treatment of an eye disease or condition | |
| AU2016904360A0 (en) | Pharmaceutical composition for treatment of an eye disease or condition | |
| AU2018900077A0 (en) | Pharmaceutical composition for treatment of an eye disease or condition | |
| HK1244680A1 (zh) | 用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物 | |
| BR112017005523A2 (pt) | formulações oculares para liberação de fármaco e proteção do segmento anterior do olho | |
| EP3129054A4 (en) | Methods and compositions for the treatment of ocular diseases and disorders |